Quality and Safety Intervention: Improving Care of Patients Undergoing B Cell-Targeted Therapies.
Iris Otani, Roxane Labrosse, Daniel V DiGiacomo et al.
✦ AI-curated · Sources linked
Case in brief
This review describes two illustrative cases involving patients receiving B cell-targeted therapies (BCTT). The abstract does not provide their individual presentations, test results, diagnoses, or outcomes. It highlights the clinical concern that BCTT may be associated with hypogammaglobulinemia and increased infection risk, and that an underlying inborn error of immunity may also be relevant. The authors discuss evaluating immunoglobulin levels and B-cell flow cytometry before treatment and periodically afterward to inform individualized assessment and management.
Diagnostic / clinical pearl
In patients receiving BCTT, assess immunoglobulin levels and B-cell flow cytometry before therapy and periodically during treatment; consider whether clinical or immunologic red flags suggest an underlying inborn error of immunity.
Why it matters
Recognizing secondary immune deficiency and possible underlying inborn errors of immunity can inform tailored consideration of antimicrobial prophylaxis or immunoglobulin replacement, with the aim of reducing morbidity and mortality.